Compare SPSC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPSC | MLYS |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2009 | 2023 |
| Metric | SPSC | MLYS |
|---|---|---|
| Price | $59.95 | $23.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $100.89 | $48.67 |
| AVG Volume (30 Days) | 753.5K | ★ 1.0M |
| Earning Date | 04-23-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.59 | ★ 37.43 |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $220,566,000.00 | N/A |
| Revenue This Year | $8.91 | N/A |
| Revenue Next Year | $7.30 | N/A |
| P/E Ratio | $24.37 | ★ N/A |
| Revenue Growth | ★ 14.11 | N/A |
| 52 Week Low | $52.56 | $10.44 |
| 52 Week High | $153.16 | $47.65 |
| Indicator | SPSC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 29.67 |
| Support Level | $52.56 | $13.42 |
| Resistance Level | $64.46 | $31.09 |
| Average True Range (ATR) | 2.45 | 1.78 |
| MACD | 1.01 | -0.23 |
| Stochastic Oscillator | 55.70 | 3.38 |
SPS Commerce Inc is a provider of cloud-based supply chain management services for retailers, grocers, distributors, suppliers, and logistics firms to increase supply chain performance, optimize inventory levels and sell-through, reduce operational costs, improve order visibility, and satisfy consumer demands for a seamless omnichannel experience. Its solutions are delivered through the SPS Commerce platform and provide integrations and retail performance analytics to its customers. Its products are; Fulfillment, Analytics, and Other products like Assortment and Community also it provides one-time services such as professional services and testing and certification. The group derives revenue from subscription-based recurring revenue services.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.